← Human Trials & Peer-Reviewed Studies
[Combined therapy with calcitonin and high doses of active vitamin D3 metabolites in uremic hyperparathyroidism]
Plain-language guide to PMID 8966142 (1996): controlled clinical trial study of Calcitonin in 75 patients, hyperparathyroidism.
Key Facts
- PMID
- 8966142
- Journal
- Polskie Archiwum Medycyny Wewnetrznej
- Year
- 1996
- Study type
- Controlled Clinical Trial
- Authors
- Matuszkiewicz-Rowińska J et al. (9 authors)
What This Study Did, in Plain Language
What Was Tested
Researchers studied Calcitonin in the context of hyperparathyroidism in this controlled clinical trial publication.
Who Took Part
The study group was 75 patients.
The age groups tagged for this paper are adults, both men and women.
How the Study Was Run
A time span of 8 months appears in the methods.
What Was Measured
PubMed files the paper under topics including Bone Density, Calcitonin, Calcitriol, Hydroxycholecalciferols, Hydroxyproline, Hyperparathyroidism, Secondary and Renal Dialysis.
What This Means in Plain Language
This is a controlled clinical trial of Calcitonin in 75 patients in people with hyperparathyroidism over 8 months.
The publication is from 1996 (Polskie Archiwum Medycyny Wewnetrznej), a journal based in Poland.
More context: the Calcitonin compound page, Hyperparathyroidism research.
Our Notes on the Compound
Calcitonin: A 32-amino-acid hormone that lowers blood calcium; salmon calcitonin (Miacalcin) has been used for Paget disease and osteoporosis.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.